quisition of American Medical Instruments Holdings, Inc.
("AMI"); and any other factors referenced in our annual information form
and other filings with the applicable Canadian securities regulatory
authorities or the SEC. Given these uncertainties, assumptions and risk
factors, readers are cautioned not to place undue reliance on such
forward-looking statements. We disclaim any obligation to update any such
factors or to publicly announce the result of any revisions to any of the
forward-looking statements contained in this press release to reflect
future results, events or developments.
About Angiotech Pharmaceuticals
Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical
and medical device company with over 1,500 dedicated employees. Angiotech
discovers, develops and markets innovative treatment solutions for diseases
or complications associated with medical device implants, surgical
interventions and acute injury. To find out more about Angiotech (NASDAQ:
ANPI, TSX, ANP) please visit our website at http://www.angiotech.com.
CONTACT: Deirdre Neary, Manager, Investor Relations and Corporate
Communications, Angiotech Pharmaceuticals, Inc., (604) 222-7056,
Page: 1 2 3 4 5 6 7 8 9 Related biology technology :1
|SOURCE Angiotech Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved
. Angiotech and Rex Medical announce exclusive licensing and distribution agreement for the "Option(TM)" inferior vena cava filter2
. Angiotech showcases its Hemostream(TM) Dialysis Catheter at the Society of Interventional Radiology (SIR) Annual Meeting3
. Angiotech announces results for the fourth quarter ended December 31, 20074
. Angiotech to participate in Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference5
. Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast6
. Angiotech and Symphony Medical Announce Licensing Agreement7
. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction8
. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC9
. Angiotech to participate in RBC 2007 Healthcare Conference10
. Angiotech to participate in Bank of America 2007 Credit Conference11
. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook